Breaking News

Tweet TWEET

Response Genetics Renews Agreement With Taiho Pharmaceutical Co., Ltd. to Provide Molecular Analyses for Cancer

Response Genetics Renews Agreement With Taiho Pharmaceutical Co., Ltd. to
Provide Molecular Analyses for Cancer

LOS ANGELES, July 17, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc.
(Nasdaq:RGDX), a company focused on the development and sale of molecular
diagnostic tests that help determine a patient's response to cancer therapy,
today announced that it has extended its agreement with Taiho Pharmaceutical
Co., Ltd. to provide testing and analyses services for specified molecular
markers used in research, diagnosis and the therapeutic treatment of cancer.

Under the terms of the agreement, Response Genetics will receive a minimum of
$950,000 for services provided during the extended term of January 1 through
December 31, 2013.

"Response Genetics has and continues to provide Taiho with a comprehensive
portfolio of gene expression assays and we are pleased to extend this
relationship," said Thomas Bologna, Chairman and CEO of Response Genetics.
"Response Genetics and Taiho share a commitment to provide services that
foster the development of patient-centered medical treatment and we believe
that the testing services resulting from this collaboration will yield
actionable results important to patient care."

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical
laboratory focused on the development and sale of molecular diagnostic testing
services for cancer.The Company's technologies enable extraction and analysis
of genetic information derived from tumor cells stored as formalin-fixed and
paraffin-embedded specimens.The Company's principal customers include
oncologists and pathologists.In addition to diagnostic testing services, the
Company generates revenue from the sale of its proprietary analytical
pharmacogenomic testing services of clinical trial specimens to the
pharmaceutical industry.The Company's headquarters is located in Los Angeles,
California.For more information, please visit www.responsegenetics.com.

About Taiho Pharmaceutical Co., Ltd.

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. is an
R&D-driven specialty pharma focusing on the three fields of oncology,
allergies and immunology, and urology.In the field of oncology in particular,
Taiho Pharmaceutical is known as a leading company in Japan and around the
world for developing innovative medicines for the treatment of cancer. In
areas other than oncology, as well, the company creates quality products that
effectively treat medical conditions and can help improve people's quality of
life.The company was established in 1963 and its headquarters is located in
Tokyo, Japan.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and
the statements of representatives of the Company related thereto contain or
may contain, among other things, certain forward-looking statements, within
the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and
uncertainties.Such statements may include, without limitation, statements
with respect to the Company's plans, objectives, projections, expectations and
intentions, such as the ability of the Company, to provide clinical testing
services to the medical community, to continue to strengthen and expand its
sales force, to continue to build its digital pathology initiative, to attract
and retain qualified management, to continue to strengthen marketing
capabilities, to expand the suite of ResponseDX® products, to continue to
provide clinical trial support to pharmaceutical clients, to enter into new
collaborations with pharmaceutical clients, to enter into areas of companion
diagnostics, to continue to execute on its business strategy and operations,
to continue to analyze cancer samples and the potential for using the results
of this research to develop diagnostic tests for cancer, the usefulness of
genetic information to tailor treatment to patients, and other statements
identified by words such as "project," "may," "could," "would," "should,"
"believe," "expect," "anticipate," "estimate," "intend," "plan" or similar
expressions.

These statements are based upon the current beliefs and expectations of the
Company's management and are subject to significant risks and uncertainties,
including those detailed in the Company's filings with the Securities Exchange
Commission.Actual results, including, without limitation, actual sales
results, if any, or the application of funds, may differ from those set forth
in the forward-looking statements.These forward-looking statements involve
certain risks and uncertainties that are subject to change based on various
factors (many of which are beyond the Company's control).The Company
undertakes no obligation to publicly update forward-looking statements,
whether because of new information, future events or otherwise, except as
required by law.

CONTACT: Investor Relations Contact:
         Peter Rahmer
         Trout Group
         646-378-2973
        
         Company Contact:
         Thomas A. Bologna
         Chairman & Chief Executive Officer
         323-224-3900

Response Genetics Logo
 
Press spacebar to pause and continue. Press esc to stop.